【摘要】 目的评价吉西他滨单药维持治疗晚期非小细胞肺癌的疗效及安全性。方法选择秦皇岛市第二医院2006-2010年确诊的ⅢB~Ⅳ期非小细胞肺癌患者,经4周期标准紫杉醇、顺铂化疗方案治疗病情未进展的患者86例,随机分为治疗组和对照组,治疗组43例给予吉西他滨单药维持及最佳支持治疗,对照组43例给予最佳支持治疗,观察比较两组患者的疗效、生活质量及药物毒副作用。结果观察组治疗疗效和生活质量方面的总有效率分别为88.4%、95.3%,均明显高于对照组的69.8%、79.1%,组间差异均有统计学意义(P<0.05);治疗组的毒副作用发生情况明显低于对照组,两组间差异有统计学意义(P<0.05)。结论吉西他滨单药维持治疗晚期非小细胞肺癌临床疗效满意,安全性高,是最佳的治疗方案之一。更多还原

【Abstract】 Objective To assess the efficacy and safety of gemcitabine in the maintenance treatment of advanced non-small cell lung cancer.Methods Eighty-six patients who were diagnosed with advanced non-small cell lung cancer in the Second Hospital of Qinhuangdao from 2006 to 2010 were enrolled in this study.After 4 cycles of standard paclitaxel and cisplatin chemotherapy,the treatment conditions of 86 patients did not progress,and then they were randomly divided into treatment group(n=43) and control group(n=43).The patients in treatment group received gemcitabine alone in combination with best supportive care,while the patients in control group received best supportive care.The efficacy,quality of life,drug toxicity and adverse effects of two groups were compared and analyzed.Results In aspects of disease progression time and quality of life,the total effective rates of observation group were 88.4% and 95.3%,which were significantly higher than 69.8% and 79.1% of control group,and the difference was statistically significant between the two groups(P<0.05).The incidence condition of toxicity and adverse effects of treatment group were significantly less than those of control group,and the difference was statistically significant between the two groups(P<0.05).Conclusions Gemcitabine in the maintenance treatment of advanced non-small cell lung cancer has satisfactory clinical efficacy and high safety,and it is one of the best treatment options.更多还原